Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02530515 · ClinicalTrials.gov registry record · Phase 2

Ex Vivo-activated Autologous Lymph Node Lymphocytes in Treating Patients With Chronic Lymphocytic Leukemia

A Phase 2 study of Chronic Lymphocytic Leukemia and Anemia, sponsored by M.D. Anderson Cancer Center.

Completed
Registry status
Phase 2
Development phase
8
Enrollment target
1
Study location

NCT02530515 is a Phase 2 study of Chronic Lymphocytic Leukemia and Anemia that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 8 participants, below the 182-participant average among 187 other Chronic Lymphocytic Leukemia trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02530515, a Phase 2 study of Chronic Lymphocytic Leukemia and Anemia, has completed, sponsored by M.D. Anderson Cancer Center.

COMPLETED
Registry status
Phase 2
Development phase
8 participants
Enrollment target
1
Study location

Study Summary

This phase II trial studies the side effects of ex vivo-activated autologous lymph node lymphocytes infusion and to see how well they work in treating patients with chronic lymphocytic leukemia. Biological therapies, such as ex vivo-activated autologous lymph node lymphocytes, use substances made from living organisms that may stimulate or suppress the immune system in different ways and stop tumor cells from growing.

Conditions Studied

Chronic Lymphocytic Leukemia Anemia Recurrent Chronic Lymphocytic Leukemia Fever Prolymphocytic Leukemia Lymphadenopathy Night Sweats Cancer Fatigue Infectious Disorder Lymphocytosis

Interventions

  • OTHER Laboratory Biomarker Analysis
  • BIOLOGICAL Ex Vivo-activated Autologous Lymph Node Lymphocytes

Study Locations (1)

Texas

  • M D Anderson Cancer Center - Houston

Trial Details

FieldValue
Enrollment Target 8 participants
Start Date 2015-12-18
Est. Completion 2018-04-30
Phase Phase 2

Sponsor

M.D. Anderson Cancer Center

2,692 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT02530515

The ClinicalTrials.gov registry entry for NCT02530515 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 182-participant average among 187 other Chronic Lymphocytic Leukemia trials with a reported enrollment target (96% lower). The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.

The record links to 10 conditions, with Chronic Lymphocytic Leukemia appearing as the primary indexed condition, and to 2 interventions - of which Laboratory Biomarker Analysis is the first listed.

NCT02530515 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.

Frequently Asked Questions

What is clinical trial NCT02530515 about?

NCT02530515 is a clinical study titled "Ex Vivo-activated Autologous Lymph Node Lymphocytes in Treating Patients With Chronic Lymphocytic Leukemia". This phase II trial studies the side effects of ex vivo-activated autologous lymph node lymphocytes infusion and to see how well they work in treating patients with chronic lymphocytic leukemia. Biological therapies, such as ex vivo-activated autologous lymph node lymphocytes, use substances made fr...

What is the current status of trial NCT02530515?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 8 participants. The study started on 2015-12-18. Estimated completion is 2018-04-30.

What conditions does trial NCT02530515 study?

This clinical trial studies the following conditions: Chronic Lymphocytic Leukemia, Anemia, Recurrent Chronic Lymphocytic Leukemia, Fever, Prolymphocytic Leukemia.

What interventions are being tested in trial NCT02530515?

The interventions under investigation include: Laboratory Biomarker Analysis (OTHER), Ex Vivo-activated Autologous Lymph Node Lymphocytes (BIOLOGICAL).

Who is sponsoring clinical trial NCT02530515?

This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02530515 being conducted?

This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Chronic Lymphocytic Leukemia

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Chronic Lymphocytic Leukemia

All registered trials for this condition

Anemia

All registered trials for this condition

Texas

All trials with a study site in Texas

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.